Bavarian Nordic A/S (BVNRY)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Paul John Chaplin MSc, Ph.D. | CEO & President | 2.19M | -- | 1967 |
| Mr. Henrik Juuel M.Sc. | CFO & Executive VP | 1.21M | -- | 1965 |
| Mr. Russell Thirsk M.Sc. | Executive VP & COO | -- | -- | 1968 |
| Mr. Rolf Sass S?rensen | Vice President of Investor Relations & Communications | -- | -- | -- |
| Ms. Anu Helena Kerns M.Sc. | Executive VP and Chief People & Sustainability Officer | -- | -- | 1972 |
| Mr. Jean-Christophe May M.B.A., Pharm.D. | Executive VP & Chief Commercial Officer | -- | -- | 1967 |
Bavarian Nordic A/S
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 1,381
Description
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Corporate Governance
Upcoming Events
November 15, 2024 at 10:59 AM UTC
Bavarian Nordic A/S Earnings Date
Recent Events
April 6, 2020 at 12:00 AM UTC
Dividend Date
March 27, 2020 at 12:00 AM UTC
Ex-Dividend Date